Contribution of Staphylococcal Enterotoxin B to Staphylococcus aureus Systemic Infection.
Staphylococcus aureus
CA-MRSA
ST59
cytokine storm
sepsis
staphylococcal enterotoxin B
superantigen
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
29
04
2020
accepted:
14
09
2020
pubmed:
17
9
2020
medline:
12
2
2022
entrez:
16
9
2020
Statut:
ppublish
Résumé
Staphylococcal enterotoxin B (SEB), which is produced by the major human pathogen, Staphylococcus aureus, represents a powerful superantigenic toxin and is considered a bioweapon. However, the contribution of SEB to S. aureus pathogenesis has never been directly demonstrated with genetically defined mutants in clinically relevant strains. Many isolates of the predominant Asian community-associated methicillin-resistant S. aureus lineage sequence type (ST) 59 harbor seb, implying a significant role of SEB in the observed hypervirulence of this lineage. We created an isogenic seb mutant in a representative ST59 isolate and assessed its virulence potential in mouse infection models. We detected a significant contribution of seb to systemic ST59 infection that was associated with a cytokine storm. Our results directly demonstrate that seb contributes to S. aureus pathogenesis, suggesting the value of including SEB as a target in multipronged antistaphylococcal drug development strategies. Furthermore, they indicate that seb contributes to fatal exacerbation of community-associated methicillin-resistant S. aureus infection.
Identifiants
pubmed: 32937658
pii: 5906645
doi: 10.1093/infdis/jiaa584
pmc: PMC8161638
doi:
Substances chimiques
Enterotoxins
0
enterotoxin B, staphylococcal
39424-53-8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1766-1775Subventions
Organisme : NIAID NIH HHS
ID : R21 AI142243
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI000904
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
Nature. 1983 Oct 20-26;305(5936):709-12
pubmed: 6226876
Int J Antimicrob Agents. 2013 Sep;42(3):211-9
pubmed: 23871455
Am J Pathol. 2011 Jun;178(6):2760-73
pubmed: 21641398
Infect Immun. 2005 Apr;73(4):2452-60
pubmed: 15784591
Virulence. 2017 Oct 3;8(7):1148-1159
pubmed: 27925510
Lancet Infect Dis. 2013 Aug;13(8):698-708
pubmed: 23827369
J Clin Microbiol. 2007 Aug;45(8):2669-80
pubmed: 17537946
Curr Opin Microbiol. 2014 Feb;17:32-7
pubmed: 24581690
Emerg Infect Dis. 2016 Nov;22(11):1988-1991
pubmed: 27767912
J Bacteriol. 2009 Jun;191(11):3462-8
pubmed: 19329640
Antimicrob Agents Chemother. 2009 Feb;53(2):512-8
pubmed: 19029328
BMC Infect Dis. 2016 Jul 22;16:339
pubmed: 27450316
FEMS Microbiol Lett. 1996 Apr 1;137(2-3):279-84
pubmed: 8998998
Shock. 2006 Jun;25(6):647-56
pubmed: 16721274
Cell Mol Life Sci. 2010 Sep;67(18):3057-71
pubmed: 20668911
Cell Microbiol. 2012 Oct;14(10):1513-21
pubmed: 22747834
Lancet. 2010 May 1;375(9725):1557-68
pubmed: 20206987
J Infect Dis. 2013 Dec 15;208(12):2058-66
pubmed: 23922375
Lancet Infect Dis. 2009 May;9(5):281-90
pubmed: 19393958
Appl Environ Microbiol. 2009 Nov;75(21):6839-49
pubmed: 19749060
J Biol Chem. 2011 Mar 18;286(11):9737-47
pubmed: 21233204
Microbes Infect. 2001 Jun;3(7):585-94
pubmed: 11418332
Annu Rev Microbiol. 2001;55:77-104
pubmed: 11544350
Lancet. 1986 May 17;1(8490):1149-50
pubmed: 2871397
J Infect Dis. 2010 Dec 1;202(11):1690-7
pubmed: 20979456
Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75
pubmed: 24476315
J Infect Dis. 2014 Sep 15;210(6):973-81
pubmed: 24803533
Clin Microbiol Rev. 2013 Jul;26(3):422-47
pubmed: 23824366
Clin Vaccine Immunol. 2016 Dec 5;23(12):918-925
pubmed: 27707765
Nat Rev Drug Discov. 2017 Jul;16(7):457-471
pubmed: 28337021
Nat Rev Immunol. 2005 Aug;5(8):606-16
pubmed: 16056254
Antimicrob Agents Chemother. 2008 Mar;52(3):837-45
pubmed: 18086843
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30782986
Antimicrob Agents Chemother. 2003 Jan;47(1):196-203
pubmed: 12499191
Immunol Rev. 2008 Oct;225:226-43
pubmed: 18837785
Front Microbiol. 2016 Nov 15;7:1818
pubmed: 27895635
Antimicrob Agents Chemother. 2012 Oct;56(10):5401-5
pubmed: 22850509
Hum Vaccin Immunother. 2020 Jul 2;16(7):1708-1718
pubmed: 32275466
Int Immunopharmacol. 2015 Sep;28(1):354-8
pubmed: 26130567
Microbiol Spectr. 2013 Dec;1(2):
pubmed: 26184960
Sci Rep. 2016 Jun 14;6:27899
pubmed: 27296890
PLoS One. 2011 Feb 03;6(2):e16764
pubmed: 21304813
J Immunol. 2005 Nov 15;175(10):6870-7
pubmed: 16272345
J Immunol. 2001 Jan 1;166(1):669-77
pubmed: 11123352
Nat Med. 2007 Dec;13(12):1510-4
pubmed: 17994102
Nat Microbiol. 2019 Jul;4(7):1114-1119
pubmed: 30936487
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5883-8
pubmed: 19293374
Vaccines (Basel). 2020 Mar 18;8(1):
pubmed: 32197534
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10102-7
pubmed: 12110733
Plasmid. 2006 Jan;55(1):58-63
pubmed: 16051359